Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth Pharmaceuticals top 5 break $1bn

Wyeth Pharmaceuticals top 5 break $1bn

1st February 2006

Wyeth Pharmaceuticals’ biggest five products have jointly produced net revenue of over $1 billion.

The company’s results for 2005 showed net revenue of $18.8 billion, a rise of eight per cent, and net income of $3.7 billion, a massive leap from $1.2 billion in 2004.

Wyeth president and chief executive Robert Essner said: “Wyeth demonstrated strong product performance and 2005 was a year of significant strategic accomplishment.

“With strong growth from biotechnology products such as Enbrel and our vaccine, Prevnar, and contributions from our core pharmaceutical products such as Effexor and Protonix, Wyeth is in the strongest competitive position in its history with five product franchises exceeding one billion dollars in annual revenues.”

He went on to explain the company filed two New Drug Applications (NDAs) in 2005 and is working toward five more for new products in the next 18 months.

track© Adfero Ltd

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.